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Abstract
Although many efforts have been directed to improve atrial fibrillation transcatheter ablation safety, thromboembolism to the brain 
remains one of the major complications. In fact several studies have confirmed occurrence of silent cerebral embolic lesions by post-
procedure magnetic resonance imaging, the present review will focus on the possible mechanisms leading to silent cerebral embolism in an 
attempt to provide recommendations holding the potential to reduce the incidence of this clinically relevant complication. 
Introduction
Transcatheter ablation of atrial fibrillation (AF) is a well-established 
treatment for symptomatic patients refractory to antiarrhythmic 
drugs, aiming to restore sinus rhythm, improve AF related symptoms 
and prevent AF related complications. Efficacy of transcatheter AF 
ablation is satisfactory in experienced centers, and, according to 
present data, is considered superior to any antiarrhythmic drug.1,2 
Many efforts have been made over the past years to improve safety 
of catheter AF ablation. As an invasive procedure, it carries a risk 
of local and systemic complications, the most harmful being cardiac 
tamponade and stroke. Despite the introduction of new catheters, 
energy sources, new imaging and navigation tools,3 the risks deriving 
from the procedure have not been cancelled, and cerebrovascular 
accidents remain in fact one of the most feared and frequent 
complications, ranging from 0.5 to 1.0%.4
Besides symptomatic cerebral events, AF ablation also carries a 
risk of silent cerebral embolic lesions. Performing cerebral magnetic 
resonance imaging (MRI) before and after catheter ablation, Lickfett 
et al. first reported in a small group of patients the detection of 
new silent cerebral ischemias (SCI),5 and this was subsequently 
confirmed by our group in a larger population of patients.6 Given that 
SCI, frequently found in patients with carotid disease, hypertensive 
cerebrovascular disease or AF, relate to neurocognitive impairment 
and dementia7,8,9,10,11,12 silent cerebral embolism following 
transcatheter ablation warrants careful consideration.
Pathophysiology of Silent Embolic Lesions
The origin of SCI during transcatheter ablation is mainly 
consequent to three mechanisms: clot formation, char formation and 
air/gas embolism. Any foreign body introduced in the blood pool 
bing potentially thrombogenic, clot formation may be expected on 
ablation and mapping catheters and sheaths. Char formation may 
instead be induced by the energy source on the tissue. Eventually air 
embolism may derive from catheters insertion and mobilization, but 
also from radiofrequency (RF) induced high temperatures producing 
intravascular gas bubbles.
Introduction of any foreign body into the blood pool stimulates 
clot formation.13,14 The 2012 ESC Consensus on AF ablation 
recommends to maintain an activated clotting time (ACT) between 
300 and 400 seconds during the procedure, to limit both thrombotic 
and hemorrhagic complications.15 In fact, a study by Ren et al. 
reported a lower incidence of spontaneous echo contrast and thrombi 
in the left atrium, detected by intracardiac echocardiography when 
ACT was maintained over 300 seconds during the procedure.16 This 
confirms that a stronger heparinization during the procedure may 
be helpful to avoid thromboembolic complications. Furthermore, 
transseptal puncture performed to reach left atrium and pulmonary 
veins when a patent foramen ovale is not present, causes platelet 
activation.17 requiring administration of a bolus of heparin before 
this procedural step.15
Char formation is indeed intrinsic to ablation techniques and 
energy sources used during the procedure. The most frequently 
used energy source is Radiofrequency (RF). RF produces thermal 
damage to the atrial tissue and is responsible of electrical conduction 
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microembolic signals at transcranial Doppler27 and cerebral lesions 
following embolization of air microbubbles have been described 
using cerebral MRI in animal studies,28 the clinical impact in humans 
remains uncertain.
In the meantime, considering energy sources used for ablation, 
by transcranial Doppler, Sauren et al. have demonstrated a lower 
incidence of microembolic signals during catheter AF ablation using 
cryoballoon or irrigated RF catheters compared to conventional RF 
catheters.29
Finally, air embolism may be related to the introduction of ablation 
devices.30,31 Careful catheter handling, avoidance of multiple catheter 
exchanges and continuous heparin flushing may therefore be useful 
in reducing the risk of SCI.
Current Literature on Silent Cerebral Ischemias Following 
Transcatheter Atrial Fibrillation Ablation
Evidence on the incidence of SCI following AF transcatheter 
ablation is summarized in Table 1. The first study detecting 
asymptomatic cerebral embolism at MRI scan following AF catheter 
ablation by open-irrigated RF catheter reported a 10% incidence of 
new SCI in a small population of 20 patients.5
Shortly after our group performed a study on 232 patients 
reporting a 14% incidence of SCI following AF ablation.6 In this 
study the ACT value maintained during the procedure strongly 
related to the incidence of SCI: 9% of patients with an ACT > 250 
reported SCI following the procedure compared to 17% within those 
maintaining lower ACT values. Another parameter independently 
related to SCI incidence following the procedure was electric or 
pharmacological cardioversion in case of persistent AF at the end 
of procedure. Clinical parameters such as age, hypertension, diabetes 
mellitus, previous history of stroke, type of AF, and pre-ablation 
antithrombotic treatment did not relate to incidence of SCI.
Another study by Schrinkel et al., performing cerebral MRI before 
and after AF ablation by irrigated RF catheter in 53 patients with 
block, isolation of triggers and interruption of circuits underlying 
AF initiation and maintenance. On the flip side it may become 
potentially harmful, causing endothelial layer damage and coagulation 
cascade activation, eventually leading to thrombus formation.18,19 
Ablation catheters, despite been studied and designed to reduce the 
electrode-endothelium interface temperature, thermal thrombus and 
char formation at the catheter tip remains one of the mechanisms 
responsible of the thromboembolic risk.20
Char formation is related to heat-induced denaturization of blood 
proteins, and can occur despite high levels of anticoagulation. In 
this setting, the introduction of open-irrigated catheters permitted a 
more efficient heat control achieving reduced thrombus formation in 
animal models.21 These catheters are, characterized by a continuous 
saline irrigation, which allows a prompt and effective heat dispersion, 
ensure interface temperature reduction, obviating tissue overheating.
Eventually, alternative energy sources, in particular cryoenergy, 
have been proposed. Cryoenergy reported lower platelet and fibrin 
activation,17 leading to lower incidence of thrombus formation in 
vitro, by preserving the endothelial layer during ablation22; results 
are however contradictory, recent studies reported similar levels of 
platelet activity and coagulation activation by cryoenergy and RF.23
The third mechanism of cerebrovascular damage is air/gas 
embolism. Gas microbubble formation has been demonstrated 
during experimental models treated by elevated temperatures, 
with two different patterns24: type 1, or scattered microbubbles, 
with a concentration <1 μl per minute of ablation, reflecting early 
tissue overheating; and type 2, or continuous microbubbles, with 
a concentration >1 μl per minute of ablation, reflecting important 
impedance rise during RF delivery. The pattern of microbubbles is 
predicted by tissue-electrode interface temperature, and not by RF 
power or catheter tip temperature.25,26 The direct visualization of these 
microbubbles by intracardiac echocardiography has been suggested 
to improve ablation safety and reduce endothelial damage by guiding 
energy titration.24 Although microbubbles have been related to 
RF: radiofrequency. CRYO: cryoenergy. PVAC: pulmonary vein ablation catheter. ACT: activated clotting time. ECV: electrical cardioversion. OAC: oral anticoagulation. E1-E10: electrode1-electrode10.
Figure 1: Incidence of silent cerebral ischemias according to different ablation tools and procedural strategies introduced to reduce silent embolism burden.
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uninterrupted OAC in 131 consecutive patients. After the procedure, 
they unexpectedly found a 12.2% incidence of new SCI at cerebral 
MRI,39 not different from that reported among patients undergoing 
heparin bridging, highlighting the fact that clot formation is 
not the sole thromboembolic mechanism.47 In this dataset age, 
spontaneous echo contrast in the left atrium, complex fractionated 
atrial electrograms (CFAE) ablation and intraprocedural electrical 
cardioversion emerged as SCI predictors.
Ablation tools and energy sources have impact on SCI incidence. 
The pulmonary vein ablation catheter (PVAC) is a duty-cycle phased 
RF ablation catheter ensuring rapid and simple procedures thanks 
to its ability both to map and ablate. The preset energy settings 
allow to deliver simultaneously unipolar and bipolar current with 
an erogated/not erogated ratio of 10-90% over time, a temperature 
target of 60° C and a low power output, which enables lesion depth 
control, reporting promising safety and outcome results accompanied 
by reduction in fluoroscopy and procedural times.48,49,50 Surprisingly, 
in a study enrolling 183 patients to compare the incidence of SCI by 
PVAC, irrigated RF and cryoballoon, the PVAC technology reported 
an unsuspected higher, 38.9%, incidence of SCI compared to 8.3% 
by RF and 5.6% by cryoenergy41. Similar results have subsequently 
been confirmed by another multicenter study.42
In order to explain this SCI excess by PVAC, an animal model 
has been designed allowing the detection of gas and solid particles 
during catheter introduction, withdrawal, manipulation, and energy 
delivery51. Type 1 (<1 μl per minute of ablation) gas bubbles during 
PVAC ablation resulted more common during bipolar ablation than 
in unipolar mode, while type 2 (>1 μl per minute of ablation) gas 
bubble production was high when electrodes 1 and 10 were in close 
paroxysmal AF, confirmed an 11% incidence of SCI. Concomitant 
coronary artery disease, left ventricular dilatation and left ventricular 
hypertrophy emerged as predictors of this complication.34 On the 
other side higher incidence of SCI was reported by Deneke et al. 
enrolling 86 patients undergoing AF ablation by irrigated RF 
catheter. In this dataset a 38% incidence of SCI at cerebral MRI was 
recorded after the procedure.35 In this case previous cerebral lesions 
at MRI and the duration of RF delivery related to SCI incidence.
Following these first reports, different protocols and ablation tools 
have been tested to reduce the incidence of SCI. A pilot study has 
been performed delaying electrical cardioversion after 4 weeks of oral 
anticoagulation (OAC) with INR 2.0-3.0 in patients with persistent 
AF at the end of the ablation procedure. All the patients underwent 
cerebral MRI the day before, the day after the ablation, and following 
sinus rhythm restoration (spontaneous or by electrical cardioversion). 
Among the total population of 95 patients, none in which electrical 
cardioversion was performed after the planned 4 weeks of OAC since 
sinus rhythm had not spontaneously been restored reported new SCI 
at the MRI scan.36
Furthermore a multicenter study underlined the safety of 
performing ablation under therapeutic OAC, reporting lower 
symptomatic thromboembolic complications compared with 
ablation under heparin, without an excessive bleeding risk46. A small 
preliminary experience on 51 patients undergoing AF ablation under 
uninterrupted OAC plus heparin during the procedure, maintaining 
ACT above 300 seconds, reported encouraging results also 
concerning silent events with only one patient (2%) positive for new 
SCI at post-procedural cerebral MRI.38 However in a larger study 
Martinek et al. performed ablation by irrigated RF catheters under 
SCI: silent cerebral ischemias. AF: atrial fibrillation. RF: radiofrequency. ACT: activated clotting time. OAC: oral anticoagulation.
Figure 2: Variables playing a potential role in the incidence of silent cerebral ischemias following transcatheter atrial fibrillation ablation.
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proximity; eventually a significant amount of air bubbles was recorded 
during PVAC catheter exchanges. Following these experiments, the 
manufacturer recommended the following amendments to reduce the 
embolic risk during ablation by PVAC: deactivate electrode pairs not 
maintaining good contact with the pulmonary veins during ablation 
(recognized by the relationship between power and temperature on 
the multi-channel generator); ensure that electrodes 1 and 10 of the 
PVAC catheter are separated; reduce air entrance by an underwater 
submerged introduction/exchange technique.
According to these recommendations, a multicenter study, the 
ERACE study [Evaluate Reduction of Asymptomatic Cerebral 
Embolism], was designed enrolling 60 patients for AF ablation 
by PVAC. The procedure was also performed under continuous 
anticoagulation (INR > 2) and with a procedural ACT target of 350 
seconds. The results, not yet published, have recently been presented 
by the manufacturer reporting a very low incidence of post-ablation 
Author, year (ref) Pts MRI timing Anticoagulation 
protocol
Source of energy SCI inci-
dence
SCI predictors Lesion follow-up
Lickfett,    2006 (5) 20 1 day pre
 1 day post
Heparin, ACT >250s Irrigated RF 10.0% - -
Gaita, 2010 (6) 232 1 day pre 
1 day post
Heparin, ACT >250s Irrigated RF 14.0% Cardioversion 
ACT<250sec
-
Schwarz,2010( ) 23 1 day pre 
1 day post 
Heparin, ACT > 300 Irrigated RF 14.3% - 3 months: verbal memory impairment
Schrickel,2010( ) 53 1 day pre
1 day post
Heparin, ACT >250s Irrigated RF 11.0% CAD, 
LV Hypertrophy
LV dilatation
Deneke, 2011 ( ) 86 1 day pre 
1 day post 
Heparin, ACT > 300 Irrigated RF 38.0% Preablation SCI 6 months: 94% regression, 
no cognitive impairment
Pianelli, 2011  ( ) 95 1 day pre 
1 day post
1 month
Heparin, ACT >250s Irrigated RF 6.0% Cardioversion SCI from 38 to 13% if cardioversion 
postponed 4 weeks post-ablation
Scaglione, 2012 ( ) 85 1 day pre Heparin, 
ACT > 300s
Irrigated RF,
Super irrigated RF
7.5%
5.0%
ACT <320sec -
Di Biase,  2011 ( ) 51 1 day pre 
1 day post
OAC, 
ACT > 300s
rriIgated RF 2.0% - -
Martinek,  2013  ( ) 131 1 day pre 
1 day post
OAC, 
ACT > 300s
Irrigated RF 12.2% Age
Echocontrast 
CFAE ablation Cardioversion
-
Ichiki, 100 1 day pre 
1 day post
Heparin, 
ACT > 250s
Irrigated RF: CFAE
Irrigated RF: 
12.2% 25.78
CFAE + PVI 7.3%
Gaita, 
2011 ( )
108 1 day pre 
1 day post
Heparin, 
ACT > 300
Irrigated RF
Cryoballoon
PVAC
8.3%
5.6%
38.9%
PVAC -
Herrera Siklody, 
2011 ( )
74 1 day pre 
1 day post
Heparin, 
ACT > 300
Irrigated RF
Cryoballoon
PVAC
7.4%
4.3%
37.5%
PVAC -
Neumann,   2011 ( ) 89 1 day pre 
1 day post
Heparin, 
ACT > 300s
Irrigated RF
Cryoballoon
6.8%
8.9%
Age 3 months: 100% regression
Haeusler,    2013 ( ) 37 1 day pre 
1 day post
Heparin, 
ACT > 300s
RF Mesh Ablator
Cryoballoon
27.0%
50.0%
Low EF
AF episode
6 months: 82% regression, 
no cognitive impairment
Wieczorek, 2013 ( ) 37 1 day pre
1 day post
OAC, 
ACT > 300s
PVAC 37.0% E1-E10 contact 1 month: 90% regression
ERACE, 
2013? ( )
60 1 day pre
1 day post 
OAC,
ACT > 350s
PVAC 1.7% - 1 month: 100% regression
Table :1 Landmark studies on new oral anticoagulants in stroke prevention in atrial fibrillation
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disappearing at six-months follow-up,44 confirming also the absence 
of neuropsychological decline with neurocognitive tests results 
unchanged during follow-up. Eventually, the study by Wieczorek et 
al. reported complete regression of 90% of the SCI detected after 
the ablation at one-month follow-up.45 Consistently, no neurological 
symptom or alteration was found in patients with positive MRI. 
According to these data, there is evidence that SCI disappear 
or at least reduce themselves under the spatial resolution power of 
the cerebral MRI over time, without evident acute neurological or 
cognitive implications. However, since it is not surely defined if SCI 
regression relates to complete neuronal recovery, excluding long-term 
neurological and cognitive impairment, physicians need to be aware 
of AF ablation related SCI. Considering the significant amount 
of patients needing one or more additional ablation procedures to 
achieve rhythm control, the potential impact of silent lesions warrants 
attention. 
Based on the afore reported literature and our personal experience 
on this topic rich of unresolved issues, the following considerations 
emerge to address and correct potential predictors of SCI (Figure 2). 
Patient selection plays a relevant role, age being one of the recurrent 
risk factors. Moreover, selection of patients with paroxysmal AF, 
small left atrial volume and short arrhythmia duration may help 
to reduce SCI incidence. Other baseline characteristics, such as 
reduced left ventricular ejection fraction, left ventricular hypertrophy 
and concomitant coronary artery disease need to be further tested. 
Considering procedural characteristics, awaiting further clinical 
evidences, in case of persistent AF after ablation, delaying electrical 
cardioversion to after one month of therapeutic OAC might play a 
role in reducing SCI occurrence. In addition total energy delivery and 
procedural duration have been reported to predict SCI incidence. The 
smaller number of catheters used, the minor number of exchanges, 
the most careful device insertion (under saline submerged technique) 
and sheath management together with long sheath withdrawal into 
the right atrium after transseptal puncture are likely related to a 
reduction in SCI consequent to air embolism. Eventually, cerebral 
MRI needs to be standardized to permit homogenous comparisons 
within patients, ablation tools and techniques.32
Conclusions:
 In conclusion additional data are needed to comprehensively 
describe the precise genesis and clearly identify correctable predictors 
of SCI to definitely improve AF transcatheter ablation safety.  
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